| . "Superiority of combining two independent trials in interim futility analysis.." Stat Methods Med Res. 2020;29(2):522-540. Pub Med |
| . "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.." Comput Methods Programs Biomed. 2019;176():211-223. Pub Med |
| . "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.." J Biopharm Stat. 2016;26(1):141-9. Pub Med |
| . "Selection of the initial design for the two-stage continual reassessment method.." J Biopharm Stat. 2017;27(3):495-506. Pub Med |
| . "Dose-finding designs for trials of molecularly targeted agents and immunotherapies.." J Biopharm Stat. 2017;27(3):477-494. Pub Med |
| . "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?." J Biopharm Stat. 2017;27(3):457-476. Pub Med |
| . "Practical designs for Phase I combination studies in oncology.." J Biopharm Stat. 2016;26(1):150-66. Pub Med |
| . "Phase II cancer clinical trials for biomarker-guided treatments.." J Biopharm Stat. 2018;28(2):256-263. Pub Med |
| . "Prospects and challenges for clinical decision support in the era of big data.." JCO Clin Cancer Inform. 2018;2():. Pub Med |
| . "The rapid enrollment design for Phase I clinical trials.." Stat Med. 2016;35(15):2516-24. Pub Med |
| . "Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.." J Natl Cancer Inst. 2012;104(3):211-27. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(4):744-55. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(1):201-12. Pub Med |
| . "Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.." J Natl Cancer Inst. 2012;104(3):211-27. Pub Med |
| . "Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates.." Bioinformatics. 2016;32(1):50-7. Pub Med |
| . "Bayesian clinical trial design using historical data that inform the treatment effect.." Biostatistics. 2019;20(3):400-415. Pub Med |
| . "Bayesian methods in clinical trials: A Bayesian analysis of ECOG trials E1684 and E1690.." BMC Med Res Methodol. 2012;12():183. Pub Med |
| . "CODEX2: Full-spectrum copy number variation detection by high-throughput DNA sequencing.." Genome Biol. 2018;19(1):202. Pub Med |
| . "Bayesian design of a survival trial with a cured fraction using historical data.." Stat Med. 2018;37(26):3814-3831. Pub Med |
| . "A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews.." Stat Methods Med Res. 2017;26(2):914-930. Pub Med |
| . "Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates.." Bioinformatics. 2016;32(1):50-7. Pub Med |
| . "Analysis of secondary phenotypes in multigroup association studies.." Biometrics. 2020;76(2):606-618. Pub Med |
| . "Factor selection and structural identification in the interaction ANOVA model.." Biometrics. 2013;69(1):70-9. Pub Med |
| . "Common variants in psychiatric risk genes predict brain structure at birth.." Cereb Cortex. 2014;24(5):1230-46. Pub Med |
| . "Estimation of treatment effect for the sequential parallel design.." Stat Med. 2011;30(30):3496-506. Pub Med |
| . "Nomenclature for alleles of the thiopurine methyltransferase gene.." Pharmacogenet Genomics. 2013;23(4):242-8. Pub Med |
| . "Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.." Oncologist. 2017;22(2):189-198. Pub Med |
| . "Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.." Stat Med. 2014;33(27):4715-33. Pub Med |
| . "Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.." Oncologist. 2017;22(2):189-198. Pub Med |
| . "MASS: Meta-analysis of score statistics for sequencing studies.." Bioinformatics. 2013;29(14):1803-5. Pub Med |
| . "Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.." Biometrics. 2012;68(2):578-86. Pub Med |
| . "A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard.." Biometrics. 2015;71(2):538-47. Pub Med |
| . "Assessing the dependence of sensitivity and specificity on prevalence in meta-analysis.." Biostatistics. 2011;12(4):710-22. Pub Med |
| . "Sparse meta-analysis with high-dimensional data.." Biostatistics. 2016;17(2):205-20. Pub Med |
| . "PreMeta: A tool to facilitate meta-analysis of rare-variant associations.." BMC Genomics. 2017;18(1):160. Pub Med |
| . "Network meta-analysis of randomized clinical trials: reporting the proper summaries.." Clin Trials. 2014;11(2):246-62. Pub Med |
| . "Meta-analysis of sequencing studies with heterogeneous genetic associations.." Genet Epidemiol. 2014;38(5):389-401. Pub Med |
| . "Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.." J Natl Cancer Inst. 2012;104(3):211-27. Pub Med |
| . "A simple and robust method for multivariate meta-analysis of diagnostic test accuracy.." Stat Med. 2017;36(1):105-121. Pub Med |
| . "Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.." Stat Med. 2014;33(9):1600-18. Pub Med |
| . "Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs.." Stat Med. 2012;31(28):3597-616. Pub Med |
| . "Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs.." Stat Med. 2013;32(23):3972-90. Pub Med |
| . "A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews.." Stat Methods Med Res. 2017;26(2):914-930. Pub Med |
| . "Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial.." Stat Methods Med Res. 2016;25(4):1596-619. Pub Med |
| . "A hybrid Bayesian hierarchical model combining cohort and case-control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias.." Stat Methods Med Res. 2016;25(6):3015-3037. Pub Med |
| . "Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation.." Stat Methods Med Res. 2015;24(6):836-55. Pub Med |
| . "Pathway-based identification of SNPs predictive of survival.." Eur J Hum Genet. 2011;19(6):704-9. Pub Med |
| . "Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics.." BMC Genomics. 2019;20(1):395. Pub Med |
| . "Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics.." BMC Genomics. 2019;20(1):395. Pub Med |
| . "Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits.." Stat Med. 2011;30(20):2551-61. Pub Med |
